Trastuzumab Modulates the Protein Cargo of Extracellular Vesicles Released by ERBB2(+) Breast Cancer Cells

Cancers overexpressing the ERBB2 oncogene are aggressive and associated with a poor prognosis. Trastuzumab is an ERBB2 specific recombinant antibody employed for the treatment of these diseases since it blocks ERBB2 signaling causing growth arrest and survival inhibition. While the effects of Trastu...

Descripción completa

Detalles Bibliográficos
Autores principales: Marconi, Silvia, Santamaria, Sara, Bartolucci, Martina, Stigliani, Sara, Aiello, Cinzia, Gagliani, Maria Cristina, Bellese, Grazia, Petretto, Andrea, Cortese, Katia, Castagnola, Patrizio
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2021
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8000509/
https://www.ncbi.nlm.nih.gov/pubmed/33809102
http://dx.doi.org/10.3390/membranes11030199

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8000509/
https://www.ncbi.nlm.nih.gov/pubmed/33809102
http://dx.doi.org/10.3390/membranes11030199

Ejemplares similares